Foclivia
pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) · Seqirus S.r.l.
EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Foclivia is used for
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Foclivia
- Active substance
- pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
- Disease area
- Influenza, Human; Immunization; Disease Outbreaks
- Medicine group
- Influenza vaccines
- ATC code
- J07BB02
- Marketing authorisation holder
- Seqirus S.r.l.
- Authorised in the EU since
- 2009
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Foclivia used for?
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
What is the active substance in Foclivia?
Foclivia contains pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted).
Who makes Foclivia?
The EU marketing authorisation holder is Seqirus S.r.l..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU